Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.61 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.61 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13262573 | 0.79 | PTGDR2 (0.59) | PTGDR2PTGDRPTGER2SLC6A9MEN1 | |
| SCHEMBL4885231 | 0.78 | PTGDR2 (0.56) | PTGDR2PTGDRMEN1MAPK1KMT2A | |
| SCHEMBL4882270 | 0.76 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2 | |
| SCHEMBL4882946 | 0.76 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2 | |
| SCHEMBL19205311 | 0.75 | PTGDR2 (0.48) | PTGDR2PTGDRMEN1MAPK1KMT2A | |
| SCHEMBL4882287 | 0.74 | PTGDR2 (0.78) | PTGDR2PTGDRPTGER2LMNA | |
| SCHEMBL2013938 | 0.74 | PTGDR2 (0.60) | PTGDR2PTGDRPTGER2MEN1KMT2A | |
| SCHEMBL1148095 | 0.73 | PTGDR2 (0.62) | PTGDR2PTGDRPTGER2SLC6A9MEN1 | |
| SCHEMBL490392 | 0.73 | PTGDR2 (0.62) | PTGDR2PTGDRPTGER2SLC6A9MEN1 | |
| SCHEMBL4878416 | 0.73 | PTGDR2 (0.74) | PTGDR2PTGDRPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269335-A1 | 2-(4-Chloro-2-cyclohexylphenoxy)propionic acid; (4-Bromo-2-cyclohexylphenoxy)propionic acid ethyl ester; ethyl-2-bromopropionate is reacted with 4-chloro-2-cyclohexylphenol in presence of cesium carbonate and N,N-dimethylfomamide; antiallergenic and antiinflammatory agent | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1756032-A1 | CRTH2 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005105727-A1 | CRTH2 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269335-A1 | 2-(4-Chloro-2-cyclohexylphenoxy)propionic acid; (4-Bromo-2-cyclohexylphenoxy)propionic acid ethyl ester; ethyl-2-bromopropionate is reacted with 4-chloro-2-cyclohexylphenol in presence of cesium carbonate and N,N-dimethylfomamide; antiallergenic and antiinflammatory agent | EPX, NR3C2, FPR2 | PTGDR2 245/4885PTGDR 151/4885PTGER2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.